Aldeyra Therapeutics, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (38)

Latest Posts

About This Stock More About This Stock
The Week In Charts: 0DTE Options - Too Good To Be True?
Video By: Dave Landry
Sunday, April 30, 2023 5:44 PM EDT
Zero-days; how Core Methodology can be used in Crypto, with current Crypto and stock market conditions; favorite stock picks.
In this video: QQQ, SMH, ALDX, IFRX, BITCOMP Also: GLD, SLV
Watch
Chart Of The Day: Aldeyra - Skyrocketing
Article By: Jim Van Meerten
Tuesday, April 11, 2023 11:15 AM EDT
Revenue is expected to grow by 2,045.80% next year. Earnings are estimated to increase by 16.90% next year and continue to compound at an annual rate of  73.70% for the next 5 years.
In this article: ALDX
Read
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Article By: Benzinga
Saturday, April 27, 2019 6:05 PM EDT
Biotech stocks staged a recovery this week after being in the red in the previous two weeks.
In this article: BTX, BOLD, REGN, BIIB, GWPH, ALDX, HRTX, IONS, ADAP, NBRV, BHVN, NVS, SNY, RHHBY, ABBV
Read
RegeneRx Versus Restasis: Who Hits The $2 Billion Dry-Eye Jackpot?
Article By: Shock Exchange
Wednesday, October 4, 2017 6:29 PM EDT
A manhunt is on for the next dry-eye disruptor. RGRX and ALDX are two candidates. RGRX just completed Phase 3 testing. Its drug has shown success in head-to-head comparisons with Restasis and Xiidra. Will RGRX hit the dry-eye jackpot?
In this article: RGRX, ALDX, AGN Also: SHPG
Read
Aldeyra Raises Additional Capital To Fund Dry Eye Treatment
Article By: Shock Exchange
Wednesday, September 27, 2017 11:55 AM EDT
ALDX recently raised nearly $27MM to fund its dry eye treatment. Fresh capital gives ALDX flexibility to partner with big pharma for drug development or go it alone. The dry eye market offers huge upside for a new entrant. ALDX is a buy.
In this article: ALDX Also: AGN, SHPG, GILD, MRK
Read

Latest Tweets for $ALDX

No tweets yet!

PARTNER HEADLINES